Greenwood Gearhart Inc. boosted its stake in shares of Stryker Corporation (NYSE:SYK) by 1.4% during the first quarter, Holdings Channel reports. The fund owned 40,476 shares of the medical technology company’s stock after buying an additional 543 shares during the period. Stryker Corporation comprises about 2.0% of Greenwood Gearhart Inc.’s holdings, making the stock its 26th largest position. Greenwood Gearhart Inc.’s holdings in Stryker Corporation were worth $5,329,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently modified their holdings of the stock. Bollard Group LLC increased its stake in Stryker Corporation by 0.4% in the first quarter. Bollard Group LLC now owns 829 shares of the medical technology company’s stock worth $109,000 after buying an additional 3 shares in the last quarter. Assetmark Inc. increased its stake in Stryker Corporation by 0.3% in the first quarter. Assetmark Inc. now owns 1,274 shares of the medical technology company’s stock worth $168,000 after buying an additional 4 shares in the last quarter. Blue Chip Partners Inc. increased its stake in Stryker Corporation by 0.3% in the first quarter. Blue Chip Partners Inc. now owns 1,775 shares of the medical technology company’s stock worth $234,000 after buying an additional 6 shares in the last quarter. Guardian Life Insurance Co. of America increased its stake in Stryker Corporation by 0.8% in the first quarter. Guardian Life Insurance Co. of America now owns 1,199 shares of the medical technology company’s stock worth $158,000 after buying an additional 9 shares in the last quarter. Finally, Baystate Wealth Management LLC increased its stake in Stryker Corporation by 2.1% in the first quarter. Baystate Wealth Management LLC now owns 1,066 shares of the medical technology company’s stock worth $139,000 after buying an additional 22 shares in the last quarter. 73.99% of the stock is currently owned by institutional investors and hedge funds.

Stryker Corporation (NYSE:SYK) traded down 0.47% during trading on Thursday, hitting $144.50. 169,030 shares of the stock were exchanged. The firm’s 50 day moving average price is $143.54 and its 200-day moving average price is $135.29. The stock has a market cap of $54.05 billion, a price-to-earnings ratio of 32.25 and a beta of 0.80. Stryker Corporation has a 1-year low of $106.48 and a 1-year high of $148.84.

Stryker Corporation (NYSE:SYK) last posted its quarterly earnings results on Thursday, July 27th. The medical technology company reported $1.53 earnings per share for the quarter, beating analysts’ consensus estimates of $1.51 by $0.02. Stryker Corporation had a return on equity of 24.26% and a net margin of 14.22%. The business had revenue of $3.01 billion for the quarter, compared to analysts’ expectations of $2.98 billion. During the same quarter in the prior year, the business earned $1.39 EPS. The firm’s revenue for the quarter was up 6.1% on a year-over-year basis. On average, analysts anticipate that Stryker Corporation will post $6.50 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, October 31st. Investors of record on Friday, September 29th will be paid a $0.425 dividend. This represents a $1.70 dividend on an annualized basis and a yield of 1.17%. The ex-dividend date of this dividend is Thursday, September 28th. Stryker Corporation’s dividend payout ratio (DPR) is presently 37.95%.

COPYRIGHT VIOLATION NOTICE: This story was posted by Watch List News and is the property of of Watch List News. If you are reading this story on another website, it was illegally copied and republished in violation of US and international copyright and trademark laws. The original version of this story can be accessed at https://www.watchlistnews.com/greenwood-gearhart-inc-has-5-33-million-position-in-stryker-corporation-syk/1470943.html.

A number of research firms recently commented on SYK. Zacks Investment Research raised shares of Stryker Corporation from a “hold” rating to a “buy” rating and set a $166.00 price objective on the stock in a report on Tuesday, August 1st. BidaskClub downgraded shares of Stryker Corporation from a “buy” rating to a “hold” rating in a report on Monday, July 31st. Cowen and Company reissued a “buy” rating and issued a $160.00 price objective (up previously from $150.00) on shares of Stryker Corporation in a research report on Sunday, July 30th. Stifel Nicolaus boosted their price objective on shares of Stryker Corporation from $151.00 to $158.00 and gave the company a “buy” rating in a research report on Friday, July 28th. Finally, Oppenheimer Holdings, Inc. set a $148.00 price objective on shares of Stryker Corporation and gave the company a “hold” rating in a research report on Friday, July 28th. Three investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and twelve have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $144.03.

In other Stryker Corporation news, insider David Floyd sold 19,305 shares of the stock in a transaction on Wednesday, July 12th. The stock was sold at an average price of $144.56, for a total transaction of $2,790,730.80. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Lonny J. Carpenter sold 5,000 shares of the stock in a transaction on Friday, August 4th. The stock was sold at an average price of $146.36, for a total value of $731,800.00. Following the transaction, the insider now owns 88,207 shares in the company, valued at approximately $12,909,976.52. The disclosure for this sale can be found here. In the last 90 days, insiders sold 32,810 shares of company stock worth $4,754,958. 7.40% of the stock is owned by company insiders.

Stryker Corporation Company Profile

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK).

Institutional Ownership by Quarter for Stryker Corporation (NYSE:SYK)

Receive News & Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.